MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MESO • US5907174016

17.34 USD
+0.15 (+0.87%)
At close: Feb 3, 2026
17.34 USD
0 (0%)
After Hours: 2/3/2026, 8:00:00 PM
Fundamental Rating

3

MESO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. MESO has a bad profitability rating. Also its financial health evaluation is rather negative. MESO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • MESO had negative earnings in the past year.
  • In the past year MESO has reported a negative cash flow from operations.
  • In the past 5 years MESO always reported negative net income.
  • In the past 5 years MESO always reported negative operating cash flow.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • MESO's Return On Assets of -13.02% is amongst the best of the industry. MESO outperforms 82.06% of its industry peers.
  • With an excellent Return On Equity value of -17.10%, MESO belongs to the best of the industry, outperforming 84.92% of the companies in the same industry.
Industry RankSector Rank
ROA -13.02%
ROE -17.1%
ROIC N/A
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

1.3 Margins

  • Looking at the Gross Margin, with a value of 70.17%, MESO belongs to the top of the industry, outperforming 81.49% of the companies in the same industry.
  • MESO's Gross Margin has improved in the last couple of years.
  • MESO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

  • MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MESO has more shares outstanding
  • The number of shares outstanding for MESO has been increased compared to 5 years ago.
  • Compared to 1 year ago, MESO has an improved debt to assets ratio.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 5.45 indicates that MESO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of MESO (5.45) is better than 73.66% of its industry peers.
  • MESO has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.12, MESO is doing worse than 62.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 5.45
ROIC/WACCN/A
WACC9.08%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • MESO has a Current Ratio of 1.99. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.99, MESO is not doing good in the industry: 75.38% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.77 indicates that MESO should not have too much problems paying its short term obligations.
  • The Quick ratio of MESO (1.77) is worse than 76.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.77
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

  • MESO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.05%.
  • MESO shows a strong growth in Revenue. In the last year, the Revenue has grown by 191.39%.
  • MESO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.76% yearly.
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.77%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%458.55%

3.2 Future

  • MESO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.01% yearly.
  • The Revenue is expected to grow by 119.79% on average over the next years. This is a very strong growth
EPS Next Y83.69%
EPS Next 2Y57.27%
EPS Next 3Y48.95%
EPS Next 5Y40.01%
Revenue Next Year564.42%
Revenue Next 2Y206.24%
Revenue Next 3Y175.67%
Revenue Next 5Y119.79%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • MESO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • MESO's earnings are expected to grow with 48.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.27%
EPS Next 3Y48.95%

More info and screens

0

5. Dividend

5.1 Amount

  • MESO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (2/3/2026, 8:00:00 PM)

After market: 17.34 0 (0%)

17.34

+0.15 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29
Earnings (Next)02-25
Inst Owners18.86%
Inst Owner Change-2.04%
Ins Owners17.95%
Ins Owner ChangeN/A
Market Cap2.24B
Revenue(TTM)17.20M
Net Income(TTM)-102.14M
Analysts82
Price Target20.25 (16.78%)
Short Float %2.9%
Short Ratio11.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.73%
EPS NQ rev (1m)0.57%
EPS NQ rev (3m)0.71%
EPS NY rev (1m)0.57%
EPS NY rev (3m)74.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)74.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 130.09
P/FCF N/A
P/OCF N/A
P/B 3.74
P/tB 87.34
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.13
BVpS4.63
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.02%
ROE -17.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.17%
FCFM N/A
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
F-Score6
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 3.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.77
Altman-Z 5.45
F-Score6
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.02%
Cap/Sales(5y)7.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.77%
EPS Next Y83.69%
EPS Next 2Y57.27%
EPS Next 3Y48.95%
EPS Next 5Y40.01%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%458.55%
Revenue Next Year564.42%
Revenue Next 2Y206.24%
Revenue Next 3Y175.67%
Revenue Next 5Y119.79%
EBIT growth 1Y-23.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.38%
EBIT Next 3Y95.39%
EBIT Next 5YN/A
FCF growth 1Y-3.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.09%
OCF growth 3YN/A
OCF growth 5YN/A

MESOBLAST LTD- SPON ADR / MESO FAQ

What is the ChartMill fundamental rating of MESOBLAST LTD- SPON ADR (MESO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MESO.


What is the valuation status for MESO stock?

ChartMill assigns a valuation rating of 1 / 10 to MESOBLAST LTD- SPON ADR (MESO). This can be considered as Overvalued.


Can you provide the profitability details for MESOBLAST LTD- SPON ADR?

MESOBLAST LTD- SPON ADR (MESO) has a profitability rating of 3 / 10.